DEFI Gestion logo

DEFI Gestion

Europe, Vaud, Switzerland, Lausanne

Description

DEFI Gestion SA has close to CHF 200 million in assets under management, for institutional as well as individual clients.

Investor Profile

DEFI Gestion has made 4 investments, with 0 in the past 12 months and 0% as lead.

Stage Focus

  • Post Ipo Equity (50%)
  • Series B (25%)
  • Series A (25%)

Country Focus

  • Switzerland (100%)

Industry Focus

  • Biotechnology
  • Health Care
  • Medical Device
  • Biopharma
  • Medical
  • Therapeutics
circle-line
FAQ

Frequently Asked Questions

Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.

Who does DEFI Gestion frequently co-invest with?

Gimv
Europe, Antwerpen, Belgium, Antwerpen
Co-Investments: 1
Innovation Capital
Europe, Ile-de-France, France, Paris
Co-Investments: 1
Sectoral Asset Management
North America, Quebec, Canada, Montréal
Co-Investments: 1
VI Partners
Europe, Schwyz, Switzerland, Altendorf
Co-Investments: 3
Ysios Capital
Europe, Pais Vasco, Spain, San Sebastian
Co-Investments: 1
Andera Partners
Europe, Ile-de-France, France, Paris
Co-Investments: 1
Neomed Management
Europe, Oslo, Norway, Oslo
Co-Investments: 3
VINCI CAPITAL
Europe, Vaud, Switzerland, Lausanne
Co-Investments: 2
CE
Europe, Ile-de-France, France, Paris
Co-Investments: 1
Reference Capital SA
Europe, Geneve, Switzerland, Genève
Co-Investments: 2

What are some of recent deals done by DEFI Gestion?

NanoPowers

Lausanne, Vaud, Switzerland

NanoPowers was a medical device company that used their artificial muscle technology to improve muscle function in human beings.

BiotechnologyHealth CareMedical Device
Series AJun 1, 2010
Amount Raised: $4,500,000
Endosense

Geneva, Geneve, Switzerland

Endosense is a medical tech company focused on improving the reproducibility of catheter ablation for the treatment of cardiac arrhythmias.

BiotechnologyHealth CareMedical DeviceTherapeutics
Series BOct 27, 2009
Amount Raised: $36,000,000
Kuros Biosciences

Schlieren, Zurich, Switzerland

Kuros Biosurgery develops biomaterials and bioactive biomaterial combination products for indications in trauma, wound and spine.

BiopharmaBiotechnologyHealth CareMedical
Post Ipo EquityOct 1, 2005
Amount Raised: $4,330,754
Kuros Biosciences

Schlieren, Zurich, Switzerland

Kuros Biosurgery develops biomaterials and bioactive biomaterial combination products for indications in trauma, wound and spine.

BiopharmaBiotechnologyHealth CareMedical
Post Ipo EquityJan 1, 2005
Amount Raised: $5,433,454